scholarly article | Q13442814 |
P356 | DOI | 10.1007/S12032-010-9516-1 |
P698 | PubMed publication ID | 20390469 |
P2093 | author name string | Faysal Dane | |
Gul Basaran | |||
Selcuk Seber | |||
Taner Korkmaz | |||
Handan Kaya | |||
Ferhat Telli | |||
Bahadir Gulluoglu | |||
Hale B Caglar | |||
Cabuk Devrim | |||
Fulden P Yumuk | |||
Muharrem Kocak | |||
Serdar N Turhal | |||
P2860 | cites work | Taxanes for adjuvant treatment of early breast cancer | Q24242987 |
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
Gene expression profiling predicts clinical outcome of breast cancer | Q27860732 | ||
A gene-expression signature as a predictor of survival in breast cancer | Q27860945 | ||
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involve | Q31826117 | ||
Revision of the American Joint Committee on Cancer staging system for breast cancer | Q38432706 | ||
Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes | Q40943517 | ||
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer | Q42163501 | ||
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen | Q43233449 | ||
Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group | Q43251299 | ||
Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF. | Q43621488 | ||
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial | Q44865908 | ||
Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement | Q44968669 | ||
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases | Q45212226 | ||
Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and N | Q46378871 | ||
Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials | Q46828225 | ||
HER-2 as a target for breast cancer therapy. | Q51766984 | ||
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu | Q57578575 | ||
Benefit of taxanes as adjuvant chemotherapy for early breast cancer | Q61899631 | ||
Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy | Q67720581 | ||
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer | Q70736024 | ||
Management and survival of female breast cancer: results of a national survey by the American College of Surgeons | Q71235390 | ||
The natural history of breast cancer with more than 10 positive nodes | Q72289481 | ||
Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results | Q73443102 | ||
The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes | Q73665822 | ||
The impact of lymph node metastases on the survival of breast cancer patients with ten or more positive lymph nodes | Q73932600 | ||
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy | Q74545924 | ||
P433 | issue | 3 | |
P921 | main subject | lymph node | Q170758 |
P304 | page(s) | 726-732 | |
P577 | publication date | 2011-09-01 | |
P1433 | published in | Medical Oncology | Q2152666 |
P1476 | title | Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years? | |
P478 | volume | 28 |
Q83498856 | Factors influencing the outcome of breast cancer patients with 10 or more metastasized axillary lymph nodes |
Q37056926 | Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes |
Q33636187 | Metastatic axillary node ratio predicts recurrence and poor long-term prognosis in patients with advanced stage IIIC (pN3) breast cancer |
Q44537135 | Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes |
Q35050980 | Prognostic Factors in Operated Stage IIIC, Pathological N3a Breast Cancer Patients |
Q37056923 | Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer |
Q33759691 | The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells |
Search more.